Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZYDELIG vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Idelalisib is a selective inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), blocking the PI3K/AKT signaling pathway, leading to reduced proliferation, survival, and migration of malignant B cells.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab,Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies,Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
150 mg orally twice daily, taken with food.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life is 6.5 hours (range 4-10 hours) after oral administration, supporting twice-daily dosing.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Primarily metabolized by aldehyde oxidase (AO) and CYP3A4, with minor contributions from UGT1A4.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily hepatic metabolism, with 44% of dose excreted in feces (as metabolites) and 22% in urine (unchanged drug and metabolites).
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
84% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Mean volume of distribution is 113 L (approximately 1.4 L/kg), indicating extensive tissue distribution.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Absolute oral bioavailability is 40% (range 30-50%) due to first-pass metabolism.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), not recommended due to lack of data.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Reduce dose to 100 mg twice daily. Child-Pugh Class C: Not recommended.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Safety and efficacy not established for patients <18 years.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
No specific dose adjustment recommended, but monitor for age-related renal and hepatic function changes.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
WARNING: FATAL AND SERIOUS TOXICITIES: Hepatic, severe diarrhea/colitis, pneumonitis, and intestinal perforation. Fatal and/or serious hepatotoxicity occurred in 18% of patients. Fatal and/or serious diarrhea or colitis occurred in 14%. Fatal and/or serious pneumonitis occurred in 4%. Fatal and/or serious intestinal perforation occurred in <1%.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Hepatotoxicity: Monitor liver function tests,Severe diarrhea/colitis: Manage with supportive care and corticosteroids,Pneumonitis: Interrupt therapy and evaluate,Intestinal perforation: Discontinue if suspected,Infections: Monitor for opportunistic infections, including CMV,Neutropenia: Monitor blood counts,Embryofetal toxicity: Can cause fetal harm,Vaccinations: Avoid live vaccines during treatment
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
History of severe hypersensitivity (e.g., anaphylaxis, Stevens-Johnson syndrome) to idelalisib or any excipient
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid grapefruit and grapefruit juice (CYP3A4 inhibition increases idelalisib exposure). Take with food to reduce nausea and diarrhea.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Pregnancy Category D. First trimester: Risk of fetal malformations including neural tube defects and craniofacial anomalies based on animal studies showing embryo-fetal toxicity and teratogenicity. Second and third trimesters: Risk of fetal hematologic toxicity (leukopenia, neutropenia) and potential growth restriction. Counsel women of childbearing age to use effective contraception during treatment and for 1 month after last dose.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
No human data on presence in breast milk; risk of serious adverse reactions in breastfed infants (immunosuppression, neutropenia). M/P ratio not determined. Advise not to breastfeed during treatment and for 1 week after last dose.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No dose adjustment studies in pregnant women. Due to increased volume of distribution and altered clearance in pregnancy, therapeutic drug monitoring is not established. Use minimum effective dose. If used during pregnancy, monitor for maternal neutropenia, infections, and adjust dose per standard ANC thresholds (hold if ANC < 500/mm³; resume at reduced dose when ANC > 1000/mm³).
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Monitor for hepatotoxicity (ALT/AST elevations), severe cutaneous reactions (Stevens-Johnson syndrome), and pneumonitis. Requires hepatic function monitoring every 2 weeks for first 2 months, then monthly. Contraindicated with CYP3A4 inducers or strong inhibitors due to metabolism via CYP3A4. Dose reduction needed for moderate hepatic impairment (Child-Pugh B).
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take with food to reduce gastrointestinal side effects.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of liver problems (jaundice, dark urine, abdominal pain) or skin reactions (rash, blisters) immediately.,Use effective contraception during and for at least 1 month after treatment.,Do not stop or change dose without consulting your healthcare provider.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ZYDELIG vs ALFENTA, answered by our medical review team.
ZYDELIG is a PI3K Inhibitor Antineoplastic that works by Idelalisib is a selective inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), blocking the PI3K/AKT signaling pathway, leading to reduced proliferation, survival, and migration of malignant B cells.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ZYDELIG and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ZYDELIG is: 150 mg orally twice daily, taken with food.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ZYDELIG and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ZYDELIG is classified as Category C. Pregnancy Category D. First trimester: Risk of fetal malformations including neural tube defects and craniofacial anomalies based on animal studies showing embryo-fetal toxicity an. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.